Top 20 by rev­enue: New analy­sis high­lights huge im­pact of tax re­form on many — but not all — of the top phar­ma gi­ants

Whether it was a new, kinder US tax pol­i­cy, a big — of­ten ag­ing — fran­chise drug or a se­ries of M&A deals, 2018 was a good if not great year for many of the top 20 phar­ma com­pa­nies in the world.

But not all.

Glob­al­Da­ta crunched the num­bers for every­one and came up with the chart be­low, out­lin­ing the win­ners and losers in the multi­na­tion­al game.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER